Study guide
16.2 Pain Assessment, Opioid Titration & Breakthrough Pain Management
Singapore Nursing Board SNB
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Legal Framework & Regulatory Governing of Nursing in Singapore
1.1 Nurses and Midwives Act & SNB Regulatory Powers 1.2 Scope of Professional Nursing Practice & Accountability 1.3 Informed Consent, Confidentiality & PDPA in Healthcare
2 Chapter 2: Ethical Standards & Professional Code of Conduct
2.1 SNB Code for Nurses and Midwives & Ethical Principles 2.2 Patient Rights, Advocacy & End-of-Life Ethical Decision-Making 2.3 Safeguarding Vulnerable Patients & Mandatory Reporting
3 Chapter 3: Holistic Patient Assessment & Nursing Process
3.1 Comprehensive Physical Assessment & Vital Signs Monitoring 3.2 Early Warning Scores & Recognising the Deteriorating Patient 3.3 Nursing Diagnosis, Person-Centred Care Planning & Evaluation
4 Chapter 4: Communication, Documentation & Clinical Safety
4.1 Therapeutic Communication & Interpersonal Care Relationships 4.2 Clinical Documentation Standards & ISBAR Clinical Handover 4.3 Clinical Risk Management, Fall Prevention & Patient Safety Goals
5 Chapter 5: Infection Prevention & Control Standards
5.1 Standard & Transmission-Based Precautions (Infection Control) 5.2 Aseptic Technique, Surgical Hand Antisepsis & Wound Care Asepsis 5.3 Outbreak Management, Multi-Drug Resistant Organisms (MDROs) & Bio-waste
6 Chapter 6: Safe Medication Administration & Clinical Pharmacology
6.1 Rights of Medication Administration & High-Alert Medications 6.2 Dosage Calculations, Unit Conversions & Pediatric/Geriatric Adjustments 6.3 Pharmacokinetics, Adverse Drug Reactions & Poison Management 6.4 Medication Reconciliation, Storage & Controlled Substances Act in SG
7 Chapter 7: Intravenous Therapy, Fluid & Electrolyte Management
7.1 Fluid Balance, Electrolyte Disturbances & ABG Interpretation 7.2 Peripheral & Central Venous Line Access, Care & Complications 7.3 Blood Product Transfusion Standards, Safety & Adverse Reaction Management
8 Chapter 8: Respiratory Care & Oxygenation Management
8.1 Airway Management, Oxygen Therapy & Pulse Oximetry 8.2 Tracheostomy Care, Suctioning & Mechanical Ventilation Nursing 8.3 Nursing Care in Acute Respiratory Distress & Chronic Obstructive Pulmonary Disease
9 Chapter 9: Cardiovascular Nursing & Hemodynamic Monitoring
9.1 Cardiac Assessment, ECG Interpretation & Common Arrhythmias 9.2 Acute Coronary Syndrome, Heart Failure & Hypertensive Crises Nursing 9.3 Shock Classification, Fluid Resuscitation & Hemodynamic Monitoring
10 Chapter 10: Medical-Surgical Nursing: Gastrointestinal & Renal Systems
10.1 Enteral & Parenteral Nutrition Management 10.2 Care of Acute Abdomen, Ostomy Care & Gastrointestinal Bleeding 10.3 Acute Kidney Injury, Chronic Kidney Disease & Dialysis Nursing
11 Chapter 11: Endocrine & Metabolic Nursing Management
11.1 Diabetes Mellitus: Glycemic Control, Insulin Therapy & Complications 11.2 Management of Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.3 Thyroid, Adrenal & Pituitary Endocrine Disorders
12 Chapter 12: Neurological Nursing & Musculoskeletal Care
12.1 Neurological Assessment, Glasgow Coma Scale (GCS) & Stroke Care 12.2 Increased Intracranial Pressure (ICP) & Seizure Management 12.3 Musculoskeletal Assessment, Traction, Cast Care & Mobility Promotion
13 Chapter 13: Perioperative & Wound Management
13.1 Preoperative Assessment, Preparation & Informed Consent Verification 13.2 Intraoperative Standards, Surgical Time-Out & Anesthesia Monitoring 13.3 Postoperative Recovery, Pain Management & Wound Healing Staging
14 Chapter 14: Elder Care, Gerontological Nursing & Chronic Disease
14.1 Comprehensive Geriatric Assessment & Frailty Syndromes 14.2 Dementia, Delirium & Depression in Older Adults 14.3 Pressure Injury Prevention, Staging & Advanced Wound Dressings
15 Chapter 15: Mental Health Nursing & Psychosocial Care
15.1 Mental Health Assessment & Therapeutic Nurse-Patient Engagement 15.2 Mood Disorders, Psychosis & Crisis Intervention 15.3 Mental Health Act in Singapore, De-escalation & Patient Safety
16 Chapter 16: Palliative Care & Symptom Management
16.1 Principles of Palliative & End-of-Life Nursing Care 16.2 Pain Assessment, Opioid Titration & Breakthrough Pain Management 16.3 Advance Care Planning (ACP) & Care of the Dying Patient
17 Chapter 17: Interprofessional Collaboration & Care Coordination
17.1 Transdisciplinary Team Dynamics & Multidisciplinary Case Conferences 17.2 Care Coordination, Community Discharge Planning & Continuity of Care 17.3 Conflict Resolution & Interprofessional Communication
18 Chapter 18: Delegation, Supervision & Clinical Leadership
18.1 Principles of Delegation to Enrolled Nurses (ENs) & Ancillary Staff 18.2 Clinical Supervision, Resource Management & Ward Operations 18.3 Quality Improvement, Clinical Audit & Incident Reporting
19 Chapter 19: Evidence-Based Practice, Education & Professional Growth
19.1 Reflective Practice & SNB CPE (Continuing Professional Education) Requirements 19.2 Integrating Evidence-Based Practice (EBP) into Clinical Care 19.3 Clinical Education, Student Preceptorship & Mentorship
16.2 Pain Assessment, Opioid Titration & Breakthrough Pain Management
Key Takeaways Explain This Topic AI
Comprehensive pain assessment in palliative care evaluates the 'Total Pain' concept (physical, psychological, social, and spiritual) using validated scales such as the Numeric Rating Scale or Abbey Pain Scale.
Opioid titration follows the WHO Analgesic Ladder, establishing a regular baseline 24-hour sustained-release opioid dose paired with immediate-release opioids calculated at 10% to 15% of the total 24-hour dose for breakthrough pain.
Equianalgesic conversion factors (e.g., Oral Morphine to Subcutaneous Morphine 2:1 ratio; Oral Morphine to Oral Oxycodone 1.5:1 ratio) are essential for safe opioid rotation and route changes.
Proactive management of opioid side effects mandates regular co-prescription of stimulant and osmotic laxatives, as tolerance never develops to opioid-induced constipation.
Last updated: July 2026
- 16.2 Pain Assessment, Opioid Titration & Breakthrough Pain Management
- Comprehensive Pain Assessment in Palliative Patients
Pain is one of the most prevalent and feared symptoms in palliative nursing care. Effective pain management requires systematic, multidimensional assessment rather than relying solely on vital signs.
The Concept of "Total Pain"
Pioneer Dame Cicely Saunders established that palliative pain encompasses four interconnected domains:
Physical Pain : Tissue damage, tumor invasion, muscle spasms, visceral organ distension, bone metastases.
Psychological Pain : Anxiety, depression, fear of death, helplessness, loss of independence.
Social Pain : Financial stress, role strain within the family, isolation, worry over dependents.
Spiritual Pain : Search for meaning, guilt, spiritual distress, existential angst.
Addressing physical pain without managing psychological or spiritual distress results in refractory, unresolved pain.
Pain Assessment Tools & Classification
Nurses must assess pain location, intensity, quality, onset/duration, aggravating/relieving factors (PQRST framework), and underlying etiology:
Cognitively Intact Patients : Numeric Rating Scale (NRS 0-10), Visual Analogue Scale (VAS), or Verbal Rating Scale (VRS).
Cognitively Impaired / Dementia / Non-Verbal Patients : Validated behavioral pain tools such as the Abbey Pain Scale or PAINAD (Pain Assessment in Advanced Dementia) , evaluating vocalizations, facial expressions, change in body language, behavioral changes, and physiological changes.
Pain Etiology Classification
Nociceptive Somatic Pain : Well-localized, aching, throbbing, or stabbing pain arising from bone, skin, or musculoskeletal tissue (e.g., bone metastases). Responds well to NSAIDs and opioids.
Nociceptive Visceral Pain : Poorly localized, cramping, deep aching, or pressure from capsule stretching or hollow organ distension (e.g., hepatic capsule stretch, bowel obstruction). Responds to opioids and antispasmodics.
Neuropathic Pain : Burning, shooting, electric-shock, or lancinating pain caused by nerve compression or damage (e.g., post-herpetic neuralgia, brachial plexus invasion). Requires co-analgesics (adjuvants) such as gabapentinoids.
The WHO Analgesic Ladder & Opioid Selection
The World Health Organization (WHO) Analgesic Ladder provides a structured stepwise approach to pain pharmacotherapy:
Step 1 (Mild Pain, NRS 1-3) : Non-opioid analgesics (Paracetamol 1g PO Q6H) +/- Adjuvant.
Step 2 (Moderate Pain, NRS 4-6) : Weak opioids (Codeine, Tramadol) + Non-opioid +/- Adjuvant. (Note: In modern palliative practice, low-dose strong opioids are increasingly preferred over Step 2 weak opioids due to unpredictable CYP2D6 metabolism of codeine and tramadol) .
Step 3 (Severe Pain, NRS 7-10) : Strong opioids (Morphine, Oxycodone, Fentanyl, Methadone) + Non-opioid +/- Adjuvant.
Opioid Titration & Breakthrough Pain Calculations
When initiating Step 3 strong opioids in opioid-naive patients, regular immediate-release (IR) oral morphine (e.g., 2.5 mg to 5 mg PO Q4H) is titrated daily until pain control is established.
Sustained-Release Baseline & Breakthrough Doses
Once pain is stabilized, the total 24-hour oral morphine equivalent dose (OMED) is converted into a regular long-acting, sustained-release (SR) formulation given every 12 hours (e.g., Morphine Sustained-Release / MST Continus PO BD), paired with immediate-release opioids for breakthrough pain .
Breakthrough Pain Dose Calculation :
The individual breakthrough pain dose is calculated as 10% to 15% of the total 24-hour baseline OMED .
Breakthrough doses are prescribed every 1 to 2 hours PRN as immediate-release oral morphine syrup/tablets or subcutaneous morphine.
Clinical Calculation Scenario:
Patient Prescribed : MST (Morphine Sustained Release) 60 mg PO twice daily (Q12H).
Step 1: Calculate Total 24-Hour OMED : 60 mg × 2 = 120 mg oral morphine per 24 hours 60\text{ mg} \times 2 = 120\text{ mg oral morphine per 24 hours} 60 mg × 2 = 120 mg oral morphine per 24 hours
Step 2: Calculate Breakthrough Dose (10% - 15%) : 10 % of 120 mg = 12 mg 10\% \text{ of } 120\text{ mg} = 12\text{ mg} 10% of 120 mg = 12 mg 15 % of 120 mg = 18 mg 15\% \text{ of } 120\text{ mg} = 18\text{ mg} 15% of 120 mg = 18 mg
Prescribed breakthrough dose range: 12 mg to 15 mg PO IR Morphine Q1H-Q2H PRN .
Step 3: Daily Dose Adjustment :
If the patient requires 4 breakthrough doses in 24 hours (e.g., 4 × 15 mg = 60 mg 4 \times 15\text{ mg} = 60\text{ mg} 4 × 15 mg = 60 mg breakthrough morphine), the new total 24-hour OMED is 120 mg (baseline) + 60 mg (breakthrough) = 180 mg/24h 120\text{ mg (baseline)} + 60\text{ mg (breakthrough)} = 180\text{ mg/24h} 120 mg (baseline) + 60 mg (breakthrough) = 180 mg/24h . The new regular dose becomes MST 90 mg PO BD.
Equianalgesic Conversions & Opioid Rotation
Opioid rotation (switching from one opioid to another) is indicated when a patient experiences intolerable opioid side effects (e.g., severe hallucinations, uncontrollable nausea, opioid-induced neurotoxicity) or deteriorating renal function.
Standard Equianalgesic Ratios (Singapore Nursing Standards)
Oral Morphine to Subcutaneous / Intravenous Morphine :
Oral morphine undergoes significant first-pass hepatic metabolism. The equianalgesic conversion ratio of Oral Morphine to Subcutaneous Morphine is 2:1 (oral dose divided by 2).
Example : 30 mg Oral Morphine = 15 mg Subcutaneous Morphine.
Oral Morphine to Oral Oxycodone :
Oral Oxycodone is approximately 1.5 times more potent than oral morphine (Ratio 1.5:1 or 30 mg Oral Morphine = 20 mg Oral Oxycodone ).
Oral Morphine to Transdermal Fentanyl :
Transdermal Fentanyl is reserved for stable pain in opioid-tolerant patients (contraindicated in acute unstable pain due to slow 12-24 hour onset).
Example : 60 mg 24-hour Oral OMED ≈ \approx ≈ 25 mcg/hour Fentanyl Patch (applied every 72 hours).
Equianalgesic Conversion Matrix
Opioid / Medication Route Equianalgesic Ratio relative to Oral Morphine 30 mg Key Clinical & Nursing Considerations
Oral Morphine PO (IR / SR) 30 mg (Baseline reference) Standard Step 3 opioid; adjust dose in renal impairment (active metabolites M3G/M6G accumulate)
Subcutaneous Morphine SC / IV 15 mg (2:1 Oral to SC conversion) Preferred parenteral route in palliative care; 2x potency of oral route due to no first-pass hepatic metabolism
Oral Oxycodone PO (IR / SR) 20 mg (1.5:1 Oral Morphine to Oxycodone) Preferred alternative in renal impairment or intolerable morphine-induced hallucinations
Transdermal Fentanyl TD Patch 12.5 - 25 mcg/hr patch (60 mg OMED ≈ \approx ≈ 25 mcg/hr) Apply to clean, dry, non-hairy skin every 72 hours; NOT for acute unstable pain; avoid direct external heat
Gabapentin / Pregabalin PO Adjuvant (N/A) First-line co-analgesic for neuropathic pain; start low dose, titrate slowly, monitor for sedation/dizziness
Managing Neuropathic Pain & Co-Analgesics (Adjuvants)
Opioids have limited efficacy against pure neuropathic pain. Adjuvant medications must be co-prescribed:
Gabapentinoids : Gabapentin (starting 100-300 mg PO ON/TDS, adjusted for renal function) or Pregabalin (25-75 mg PO BD). Inhibit presynaptic voltage-gated calcium channels.
Tricyclic Antidepressants (TCAs) : Amitriptyline (10-25 mg PO ON). Inhibits serotonin and norepinephrine reuptake; caution in elderly due to anticholinergic side effects (urinary retention, sedation, dry mouth).
Corticosteroids : Dexamethasone (4 mg to 16 mg PO/IV daily in divided doses). Decreases peri-tumoral edema in spinal cord compression, brain metastases, capsular stretch pain, and malignant bowel obstruction.
Opioid Toxicity & Side Effect Management
Nurses must proactively prevent and manage opioid-related adverse effects:
Opioid-Induced Constipation (OIC) :
Crucial Rule : Patients NEVER develop tolerance to opioid-induced constipation.
Proactive Nursing Management : All patients starting Step 2 or Step 3 opioids MUST be co-prescribed a routine bowel regimen (stimulant laxative such as Senna + osmotic agent such as Lactulose or Macrogol). Bulk-forming laxatives (e.g., Psyllium/Metamucil) are contraindicated in weak palliative patients as they cause fecal impaction if fluid intake is low.
Nausea & Sedation :
Tolerance to nausea and sedation usually develops within 3 to 7 days. Prescribe short-term PRN Haloperidol 0.5-1 mg PO or Metoclopramide 10 mg PO.
Opioid Neurotoxicity & Overdose :
Manifestations: Severe sedation, confusion, vivid hallucinations, myoclonus (muscle twitching), hyperalgesia, pinpoint pupils, and respiratory depression (respiratory rate < 8-10 breaths/minute).
Emergency Management: Stop/hold opioid dose. Administer small, titrated doses of diluted intravenous Naloxone (e.g., 40 mcg to 80 mcg IV Q2-3 mins) aimed at restoring adequate ventilation (RR > 10/min) without precipitating severe withdrawal pain crisis.